AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10890384
Drug: Interleukin-2 (IL2)
RxNorm normalized name: Interleukin-2 aldesleukin
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin-2 (IL2) 5 million units/m2 once daily by constant intravenous infusion (CI) 5 days/week for 2 weeks
Trial: 10890384
Drug: Interleukin-2 (IL2)
RxNorm normalized name: Interleukin-2 aldesleukin
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin-2 (IL2) 5 million units/m2 once daily by subcutaneous bolus (SB) injection 5 days/week for 2 weeks
Trial: 30001745
Drug: Lotilaner (Credelio™)
RxNorm normalized name: lotilaner Chewable Tablet [Credelio]
DrugBank: Lotilaner (DB17992)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lotilaner (Credelio™) at 26 mg/kg (1×)
Trial: 30001745
Drug: Lotilaner (Credelio™)
RxNorm normalized name: lotilaner Chewable Tablet [Credelio]
DrugBank: Lotilaner (DB17992)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lotilaner (Credelio™) at 78 mg/kg (3×)
Trial: 30001745
Drug: Lotilaner (Credelio™)
RxNorm normalized name: lotilaner Chewable Tablet [Credelio]
DrugBank: Lotilaner (DB17992)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lotilaner (Credelio™) at 130 mg/kg (5×)
Trial: 27596059
Drug: 1-h plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-h plasma glucose >8.6mmol/l (155mg/dl)
Trial: 27596059
Drug: 1-h plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-h plasma glucose ≤8.6mmol/l (155mg/dl) and 2-h-PG <7.8mmol/l (140mg/dl)
Trial: 19380175
Drug: Concomitant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant treatment (gemcitabine for a maximum of 6 cycles plus cetuximab until progression)
Trial: 19380175
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment (gemcitabine for a maximum of 6 cycles followed by cetuximab)
Trial: 19380175
Drug: Concomitant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant treatment (CALC1-E)
Trial: 9870121
Drug: Screening and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening and treatment (experimental group)
Trial: 2233598
Drug: Nitrendipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (20 mg/day) + Acebutolol (200 mg/day)
Trial: 2233598
Drug: Nitrendipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (20 mg/day) + Hydrochlorothiazide (25 mg/day)
Trial: 24956095
Drug: Test implants
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test implants with platform switching
Trial: 16037143
Drug: ondansetron (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron (0.1 mg/kg IV)
Trial: 12421239
Drug: Levofloxacin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin (100 mg once a day) with Erythromycin (200 mg three times a day)
Trial: 12421239
Drug: Erythromycin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (200 mg three times a day)
Trial: 10696321
Drug: Topical 0.3%
RxNorm normalized name: triclosan topical 0.3% topical bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.3% ciprofloxacin
Trial: 10696321
Drug: Topical 0.3%
RxNorm normalized name: triclosan topical 0.3% topical bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.3% ofloxacin
Trial: 8698859
Drug: Cortisol infusion
RxNorm normalized name: cortisol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol infusion during euglycemia (day 1)
Trial: 6213126
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of verapamil (single dose of 80 mg)
Trial: 6213126
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of verapamil (single dose of 10 mg in 45 minutes)
Trial: 26018599
Drug: ReCharge ice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ReCharge ice cream (100g for 2 weeks before and 6 weeks after chemotherapy)
Trial: 26018599
Drug: ReCharge ice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ReCharge ice cream
Trial: 24480604
Drug: Kangaroo holding
RxNorm normalized name: dextromethorphan hydrobromide Oral Lozenge [Hold DM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kangaroo holding (1h of daily skin-to-skin contact on the chest of mother)
Trial: 24480604
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no holding restrictions, received weekly brief social visits)
Trial: 21540805
Drug: Methylprednisolone 40
RxNorm normalized name: methylprednisolone 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 40 mg bolus injection
Trial: 15528034
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C supplementation (1 g/d for a week)
Trial: 9512083
Drug: HP 228
RxNorm normalized name: HP 502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HP 228 (30 microg/kg) plus Morphine (0.15 mg/kg)
Trial: 8062152
Drug: 1 microgram
RxNorm normalized name: Alfacalcidol 1 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 microgram of 1 alpha(OH)D3 daily
Trial: 16214634
Drug: Titrated oral
RxNorm normalized name: magnesium citrate Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titrated oral appliance
Trial: 12360125
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy (n = 33)
Trial: 9989538
Drug: Intravenous doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous doxycycline (100 mg every 12 hours)
Trial: 9989538
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (other antibiotic regimens)
Trial: 2271433
Drug: Yellow fever
RxNorm normalized name: yellow fever live
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yellow fever vaccine
Trial: 7246701
Drug: Neutral hypotonic
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutral hypotonic tear preparations
Trial: 25854932
Drug: Bushen Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bushen Capsule (BSC), orally treated for 3 months
Trial: 8021910
Drug: Nifedipine coat
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine coat core 30 mg once daily
Trial: 8021910
Drug: Nifedipine coat
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine coat core 60 mg once daily
Trial: 8021910
Drug: Nifedipine coat
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine coat core (both doses)
Trial: 3415882
Drug: Premedication with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premedication with diazepam 0.14 mg kg‐1 by mouth
Trial: 3415882
Drug: Premedication with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premedication with hyoscine 6 micrograms kg‐1 + morphine 0.2 mg kg‐1 i.m.
Trial: 3415882
Drug: Lignocaine 1
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine 1 mg kg‐1 rapid i.v. injection
Trial: 31667572
Drug: Trastuzumab monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab monotherapy (arm A)
Trial: 31667572
Drug: Trastuzumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab plus mono-chemo-agent (arm B)
Trial: 24843529
Drug: Exenatide 5
RxNorm normalized name: EXENATIDE 5MCG/DOSE 1.2ML 60D PEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide 5 μg
Trial: 21255526
Drug: Exenatide (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide (both doses)
Trial: 19451281
Drug: Liposomal amikacin
RxNorm normalized name: amikacin liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal amikacin 500 mg by inhalation once daily for 14 days
Trial: 11125606
Drug: Ketorolac administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac administered preoperatively (n = 25)
Trial: 11125606
Drug: Ketorolac administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac administered at the conclusion of surgery (Control group, n = 24)
Trial: 11125606
Drug: Total fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Total fentanyl use and postoperative oral analgesic requirements
Trial: 9166164
Drug: Ampicillin-sulbactam for
RxNorm normalized name: ampicillin / sulbactam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin-sulbactam for 72 hours followed by amoxicillin-clavulanate
Trial: 9166164
Drug: Ampicillin for
RxNorm normalized name: Ampicillin for Injection
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ampicillin for 72 hours followed by amoxicillin
Trial: 2892047
Drug: Calcium 500
RxNorm normalized name: Calcium 500+D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium 500 mg plus intranasal salmon calcitonin 50 IU/day for 5 days per week
Trial: 7502689
Drug: Calcium 500
RxNorm normalized name: Calcium 500+D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium 500 mg/day
Trial: 24081023
Drug: Alendronate (ALN)
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate (ALN) 70 mg/week
Trial: 25766052
Drug: Static hamstring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Static hamstring stretching (4 exercises, 30 seconds each, performed twice with 15 seconds rest, 6 days per week for 7 weeks)
Trial: 23622915
Drug: Essential medical
RxNorm normalized name: Eucalyptus essential oil
DrugBank: Eucalyptus oil (DB11114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Essential medical therapy before PCI
Trial: 23622915
Drug: Essential medical
RxNorm normalized name: Eucalyptus essential oil
DrugBank: Eucalyptus oil (DB11114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Essential medical therapy at discharge after PCI
Trial: 23622915
Drug: Aspirin use
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin use before PCI
Trial: 23622915
Drug: Aspirin use
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin use after PCI
Trial: 23622915
Drug: β-Blocker use
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: β-Blocker use before PCI
Trial: 23622915
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy comparison based on history of myocardial infarction or revascularization before PCI
Trial: 23622915
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy likelihood based on gender and dialysis status
Trial: 20564933
Drug: Propofol (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (4 mg/kg/hr) + Ketamine (2 mg/kg/hr)
Trial: 20564933
Drug: Propofol (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (4 mg/kg/hr) + Fentanyl (3 microg/kg/hr)
Trial: 18230942
Drug: Structured Writing
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured Writing Therapy (SWT)
Trial: 26948519
Drug: Ginger (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger (500 mg)
Trial: 18204981
Drug: alteplase infusion
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: alteplase infusion plus weight-adjusted UH (24-48 h) and then enoxaparin (7 days)
Trial: 11513446
Drug: Midodrine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midodrine (5 mg three times a day, increased to 15 mg three times a day as needed)
Trial: 11513446
Drug: Fluid therapy
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid therapy (increased fluid intake, salt tablets, and counseling)
Trial: 7839092
Drug: Triple treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple treatment consisting of bismuth subnitrate, oxytetracycline, and metronidazole for 14 days
Trial: 29768465
Drug: Truncated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Truncated treatment (stopping antibiotics at Day 7)
Trial: 29768465
Drug: Continued treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued treatment (continuing antibiotics until Day 14)
Trial: 29768465
Drug: Truncated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Truncated treatment
Trial: 18826867
Drug: Different methods
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different methods for average bioequivalence evaluation including widening bioequivalence limits, scaling limits, and alternative bioavailability measures.
Trial: 8574510
Drug: BAY x
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY x 7195, 50 mg
Trial: 8574510
Drug: BAY x
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY x 7195, 100 mg
Trial: 8574510
Drug: BAY x
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY x 7195, 250 mg
Trial: 8574510
Drug: BAY x
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY x 7195, 500 mg
Trial: 8574510
Drug: BAY x
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY x 7195, 1000 mg
Trial: 11527144
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of bisoprolol once daily (o.d., n = 20)
Trial: 11527144
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of nifedipine sustained release (SR) b.i.d. (n = 20)
Trial: 20938333
Drug: Oral pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral pregabalin 150 mg/12 h
Trial: 20938333
Drug: Prazepam 10
RxNorm normalized name: prazepam 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazepam 10 mg/12 h
Trial: 12944569
Drug: Structured treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured treatment interruption for four months followed by a change in antiretroviral regimen
Trial: 12944569
Drug: Structured treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured treatment interruption
Trial: 12944569
Drug: Structured treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured treatment interruption and immediate change in regimen
Trial: 10658043
Drug: Acetazolamide (Acz;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide (Acz; 10 mg/kg body wt iv)
Trial: 8436155
Drug: Cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 400 mg orally three times a day
Trial: 28898530
Drug: Intradiscal electrothermal
RxNorm normalized name: Valrubicin Intravesical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradiscal electrothermal therapy (IDET)
Trial: 22411483
Drug: Clonidine 150
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine 150 μg and Midazolam 7.5 mg
Trial: 20973267
Drug: Canfosfamide +
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Canfosfamide + PLD (1000 mg/m² canfosfamide and 50 mg/m² PLD)
Trial: 20973267
Drug: PLD alone
RxNorm normalized name: pLDLR-Neo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLD alone (50 mg/m²)
Trial: 15809515
Drug: Chronic hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Chronic hydrocortisone treatment (40 mg daily for 1 week)
Trial: 15809515
Drug: Acute hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Acute hydrocortisone treatment (40 mg)
Trial: 8512477
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone sodium succinate (250 mg every 6 hours for 3 days) followed by oral prednisone (1 mg/kg per day for 11 days)
Trial: 1734247
Drug: Placebo (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral for 14 days)
Trial: 31106353
Drug: 4 weeks
RxNorm normalized name: risperiDONE 75 mg/4 weeks intramuscular powder for injection, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 weeks of systemic, pathogen-targeted antibiotic therapy
Trial: 31106353
Drug: 6 weeks
RxNorm normalized name: perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6 weeks of systemic, pathogen-targeted antibiotic therapy
Trial: 24009749
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg lutein supplement
Trial: 21114552
Drug: Weekly e-mail
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly e-mail messages and monthly personal e-mail messages with reporting of weight (n = 28)
Trial: 11412291
Drug: Propofol 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2.5 mg kg(‐1)
Trial: 11412291
Drug: Propofol 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 3.0 mg kg(‐1)
Trial: 9764960
Drug: Formulation I
RxNorm normalized name: Recombivax HB, Hepatitis B Vaccine (Recombinant) Pediatric/Adolescent Formulation Injectable Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation I
Trial: 9764960
Drug: Formulation II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation II
Trial: 9764960
Drug: Formulation III
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation III
Trial: 9725476
Drug: Reference capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference capsule
Trial: 8001064
Drug: 0.42% F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.42% F gel once a day for 1 year
Trial: 8001064
Drug: 1.23% F
RxNorm normalized name: 60 Second 1.23% Fluoride Treatment Dental Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.23% F gel for 4 weeks followed by 0.42% F gel daily for 1 year
Trial: 8001064
Drug: Unstimulated saliva
RxNorm normalized name: Dunaliella salina extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unstimulated saliva flow < 0.1 ml/min
Trial: 8001064
Drug: Stimulated salivary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulated salivary flow < 0.5 ml/min
Trial: 8001064
Drug: Unstimulated saliva
RxNorm normalized name: Dunaliella salina extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unstimulated saliva flow > 0.1 ml/min with 0.42% F gel
Trial: 3356120
Drug: ketoconazole 200
RxNorm normalized name: ketoconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketoconazole 200 mg administered after a fast (Treatment A)
Trial: 3356120
Drug: ketoconazole 200
RxNorm normalized name: ketoconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketoconazole 200 mg with a standardized high-fat meal (Treatment B)
Trial: 3356120
Drug: ketoconazole 200
RxNorm normalized name: ketoconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketoconazole 200 mg with a standardized high-carbohydrate meal (Treatment C)
Trial: 3356120
Drug: ketoconazole 200
RxNorm normalized name: ketoconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketoconazole 200 mg after pretreatment with glutamic acid hydrochloride 680 mg (Treatment D)
Trial: 3356120
Drug: ketoconazole 200
RxNorm normalized name: ketoconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketoconazole 200 mg in a simulated achlorhydric state (Treatment E)
Trial: 3356120
Drug: ketoconazole 200
RxNorm normalized name: ketoconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketoconazole 200 mg with glutamic acid hydrochloride in a simulated achlorhydric state (Treatment F)
Trial: 14769704
Drug: Roxithromycin therapy
RxNorm normalized name: roxithromycin
DrugBank: Roxithromycin (DB00778)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxithromycin therapy for 30 days
Trial: 14769704
Drug: No antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotic therapy (control group)
Trial: 11290877
Drug: Lanepitant 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanepitant 50 mg daily
Trial: 11290877
Drug: Lanepitant 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanepitant 100 mg daily
Trial: 11290877
Drug: Lanepitant 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanepitant 200 mg twice daily
Trial: 7803735
Drug: High-dose vecuronium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vecuronium (VEC) 400 micrograms/kg
Trial: 7803735
Drug: High-dose vecuronium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vecuronium (VEC)
Trial: 7803735
Drug: Doxacurium (DOX)
RxNorm normalized name: Doxacurium
DrugBank: Doxacurium (DB01135)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxacurium (DOX) and High-dose vecuronium (VEC)